Eric J. Sijbrands

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 195 publications

Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study.

Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study.

Journal: European journal of preventive cardiology

Published: April 23, 2026

IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies.

IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies.

Journal: Diabetes care

Published: March 13, 2026

Genetic architecture and cross-platform validation of apolipoprotein A-IV concentrations.

Genetic architecture and cross-platform validation of apolipoprotein A-IV concentrations.

Journal: Genome biology

Published: December 02, 2025

Replication of 10 novel loci involved in human plasma protein N-glycosylation using MALDI-MS and UHPLC-FD data.

Replication of 10 novel loci involved in human plasma protein N-glycosylation using MALDI-MS and UHPLC-FD data.

Journal: Glycobiology

Published: October 23, 2025

From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.

From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 13, 2024

Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.

Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.

Journal: American heart journal

Published: September 30, 2024

Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.

Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.

Journal: International journal of molecular sciences

Published: April 20, 2024

Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model.

Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model.

Journal: CPT: pharmacometrics & systems pharmacology

Published: February 02, 2024

The effects of APOE4 and familial Alzheimer's disease mutations on free fatty acid profiles in mouse brain are age- and sex-dependent.

The effects of APOE4 and familial Alzheimer's disease mutations on free fatty acid profiles in mouse brain are age- and sex-dependent.

Journal: Journal of neurochemistry

Published: February 01, 2024

Subtyping Severe Hypercholesterolemia by Genetic Determinant to Stratify Risk of Coronary Artery Disease.

Subtyping Severe Hypercholesterolemia by Genetic Determinant to Stratify Risk of Coronary Artery Disease.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: August 17, 2023

Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids.

Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids.

Journal: International journal of molecular sciences

Published: August 15, 2023

Defining type 2 diabetes polygenic risk scores through colocalization and network-based clustering of metabolic trait genetic associations.

Defining type 2 diabetes polygenic risk scores through colocalization and network-based clustering of metabolic trait genetic associations.

Journal: Genome medicine

Published: June 01, 2023

Showing 1-12 of 195

Last Updated: 09/26/2026